Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus.
Estrogen is of great importance in the regulation of uterine function. The aim of this study was to examine the individual physiological roles of each of the two receptors for estradiol, estrogen receptor (ER) alpha and ERbeta, and their potential comodulatory effects on gene expression and uterine growth using recently developed ER subtype-selective agonist ligands. The use of ER subtype-selective ligands provides an alternative, complementary approach to the use of receptor knockout mice. Administration of the ERalpha-selective ligand propyl pyrazole triol (PPT) to immature mice resulted in a significant increase in uterine weight, as well as bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression in luminal epithelial cells. PPT also increased complement component 3, lactoferrin, and glucose-6-phosphate dehydrogenase (G6PDH), and decreased androgen receptor (AR) and progesterone receptor (PR) mRNA levels in uterine tissue, as did estradiol (E(2)). However, when compared with E(2), PPT was less effective in stimulating uterine weight, complement component 3, and G6PDH expression but was as effective as E(2) in regulating lactoferrin, AR, and PR expression. In contrast to the action of the ERalpha agonist PPT, the ERbeta agonist diarylpropionitrile (DPN) did not increase uterine weight or luminal epithelial cell proliferation at a dose that reduced G6PDH and elicited a decrease in PR and AR mRNA and protein expression. Interestingly, DPN reduced the uterine weight stimulation by PPT, and enhanced the effect of PPT in decreasing uterine PR and AR mRNA. These findings with ER subtype-selective ligands indicate that ERalpha is the major regulator of estrogen function in the uterus, but that ERbeta does exert effects on some uterine markers of estrogen action. In addition, ERbeta can modulate ERalpha activity in a response-specific and dose-dependent manner.
Frasor
Jonna
J
Department of Molecular and Integrative Physiology, University of Illinois, 407 South Goodwin Avenue, Urbana, IL 61801-3704, USA.
Barnett
Daniel H
DH
Danes
Jeanne M
JM
Hess
Rex
R
Parlow
Albert F
AF
Katzenellenbogen
Benita S
BS
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003176:Complement C3 / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D005260:Female; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology; D005954:Glucosephosphate Dehydrogenase / Q000235:genetics; D007781:Lactoferrin / Q000235:genetics; D008024:Ligands; D051379:Mice; D008810:Mice, Inbred C57BL; D009570:Nitriles / Q000494:pharmacology; D009929:Organ Size; D010636:Phenols; D011720:Pyrazoles / Q000494:pharmacology; D011944:Receptors, Androgen / Q000235:genetics; D011960:Receptors, Estrogen / Q000819:agonists / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000235:genetics; D014599:Uterus / Q000166:cytology / Q000378:metabolism*
D003176:Complement C3; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D008024:Ligands; D009570:Nitriles; D010636:Phenols; D011720:Pyrazoles; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C486184:4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol; C005557:propionitrile; D005954:Glucosephosphate Dehydrogenase; D007781:Lactoferrin